ANPDFJul 171 min readAzafaros Media Release | July 16, 2024Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C Read the...
ANPDFMar 141 min readAzafaros Media Release | March 12, 2024Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients.